SCHEMBL2865637

SCHEMBL2865637

C=CCC(CO)CCCCCC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.65
ALDH1A1 P00352 2/20 0.48
TSHR P16473 3/20 0.41
CYP2D6 P10635 2/20 0.41
SPHK1 Q9NYA1 1/20 0.41
GMNN O75496 1/20 0.41
POLB P06746 1/20 0.41
THPO P40225 1/20 0.41
MTOR P42345 1/20 0.41
BLM P54132 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
CETP P11597 1/20 0.41
HTT P42858 1/20 0.41
UBE2N P61088 1/20 0.41
FAAH O00519 1/20 0.38
MEN1 O00255 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25211139 1.00 LMNA (0.65) LMNAALDH1A1TSHRCYP2D6SPHK1
SCHEMBL9280273 1.00 LMNA (0.65) LMNAALDH1A1TSHRCYP2D6SPHK1
SCHEMBL9675098 1.00 LMNA (0.65) LMNAALDH1A1TSHRCYP2D6SPHK1
SCHEMBL11093027 0.98 LMNA (0.61) LMNAALDH1A1TSHRCYP2D6SPHK1
SCHEMBL7564848 0.96 LMNA (0.59) LMNAALDH1A1TSHRCYP2D6SPHK1
SCHEMBL5831688 0.92 ALDH1A1 (0.58) LMNAALDH1A1TSHRCYP2D6SPHK1
SCHEMBL25178065 0.87 LMNA (0.50) LMNAALDH1A1TSHRFAAHFFAR4
SCHEMBL25181795 0.87 LMNA (0.50) LMNAALDH1A1TSHRFAAHFFAR4
SCHEMBL9445614 0.87 LMNA (0.50) LMNAALDH1A1TSHRFAAHFFAR4
SCHEMBL15687620 0.87 LMNA (0.50) LMNAALDH1A1TSHRFAAHFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723550-B2 Process for preparing organic compounds NOVARTIS AG (CH) 2010-05-25 US disclosed
EP-1943205-B1 PROCESS FOR PREPARING OF 2-ALKYL-3-ARYL-PROP-2 ENE-1-OLS NOVARTIS AG (CH) 2010-01-20 EP disclosed
US-20090105503-A1 Process for Preparing organic compounds NOVARTIS PHARMA AG (CH) 2009-04-23 US disclosed
EP-1943205-A1 PROCESS FOR PREPARING OF 2-ALKYL 3-ARYL PROP-2-2ENE-1-OLS Speedel Experimenta AG (CH) 2008-07-16 EP disclosed
WO-2008055941-A1 PROCESS FOR PREPARING OF 2-ALKYL-3-ARYL-PROP-2 ENE-1-OLS SPEEDEL EXPERIMENTA AG (CH) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105503-A1 Process for Preparing organic compounds C1S, C9, C5 LMNA 707/4885ALDH1A1 1478/4885TSHR 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.